Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 746

1.

The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.

Tack J, Schumacher K, Tonini G, Scartoni S, Capriati A, Maggi CA; Iris-2 investigators.

Gut. 2017 Aug;66(8):1403-1413. doi: 10.1136/gutjnl-2015-310683. Epub 2016 Apr 15.

PMID:
27196574
2.

Structure-Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position 9.

Merlino F, Brancaccio D, Yousif AM, Piras L, Campiglia P, Gomez-Monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Carotenuto A, Grieco P.

ChemMedChem. 2016 Aug 19;11(16):1856-64. doi: 10.1002/cmdc.201500607. Epub 2016 Apr 9.

PMID:
27061352
3.

Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer.

Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, Santopaolo M, Votino C, Pancione M, Piepoli A, Mazzoccoli G, Binaschi M, Bigioni M, Maggi CA, Fassan M, Laudanna C, Matarese G, Sabatino L, Colantuoni V.

Cell Death Dis. 2016 Feb 25;7:e2120. doi: 10.1038/cddis.2016.28.

4.

Gender-related differential effect of tachykinin NK2 receptor-mediated visceral hyperalgesia in guinea pig colon.

Bellucci F, Buéno L, Bugianesi R, Crea A, D'Aranno V, Meini S, Santicioli P, Tramontana M, Maggi CA.

Br J Pharmacol. 2016 Apr;173(8):1329-38. doi: 10.1111/bph.13427. Epub 2016 Mar 7.

5.

Enhanced Ca(2+) response and stimulation of prostaglandin release by the bradykinin B2 receptor in human retinal pigment epithelial cells primed with proinflammatory cytokines.

Catalioto RM, Valenti C, Maggi CA, Giuliani S.

Biochem Pharmacol. 2015 Sep 15;97(2):189-202. doi: 10.1016/j.bcp.2015.07.034. Epub 2015 Jul 30.

PMID:
26235941
6.

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.

Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group.

Ann Oncol. 2015 Oct;26(10):2155-61. doi: 10.1093/annonc/mdv317. Epub 2015 Jul 27.

7.

Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain.

Moore RA, Gay-Escoda C, Figueiredo R, Tóth-Bagi Z, Dietrich T, Milleri S, Torres-Lagares D, Hill CM, García-García A, Coulthard P, Wojtowicz A, Matenko D, Peñarrocha-Diago M, Cuadripani S, Pizà-Vallespir B, Guerrero-Bayón C, Bertolotti M, Contini MP, Scartoni S, Nizzardo A, Capriati A, Maggi CA.

J Headache Pain. 2015;16:541. doi: 10.1186/s10194-015-0541-5. Epub 2015 Jun 27.

8.

Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.

Marastoni E, Bartoli S, Berettoni M, Cipollone A, Ettorre A, Fincham CI, Mauro S, Paris M, Porcelloni M, Bigioni M, Binaschi M, Nardelli F, Parlani M, Maggi CA, Paoli P, Rossi P, Fattori D.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1603-6. doi: 10.1016/j.bmcl.2015.02.007. Epub 2015 Feb 24.

PMID:
25746815
9.

Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.

Carotenuto A, Auriemma L, Merlino F, Yousif AM, Marasco D, Limatola A, Campiglia P, Gomez-Monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Grieco P.

J Med Chem. 2014 Jul 24;57(14):5965-74. doi: 10.1021/jm500218x. Epub 2014 Jul 10.

PMID:
24992374
10.

Antagonist profile of ibodutant at the tachykinin NK(2) receptor in guinea pig isolated bronchi.

Santicioli P, Meini S, Giuliani S, Lecci A, Maggi CA.

Eur J Pharmacol. 2013 Nov 15;720(1-3):180-5.

PMID:
24436990
11.

Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation.

Terzuoli E, Meini S, Cucchi P, Catalani C, Cialdai C, Maggi CA, Giachetti A, Ziche M, Donnini S.

PLoS One. 2014 Jan 2;9(1):e84358. doi: 10.1371/journal.pone.0084358. eCollection 2014.

12.

MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer.

Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente D, Forte N, Colantuoni V.

Neoplasia. 2013 Sep;15(9):1086-99.

13.

Blockade of nociceptive sensory afferent activity of the rat knee joint by the bradykinin B2 receptor antagonist fasitibant.

Gomis A, Meini S, Miralles A, Valenti C, Giuliani S, Belmonte C, Maggi CA.

Osteoarthritis Cartilage. 2013 Sep;21(9):1346-54. doi: 10.1016/j.joca.2013.03.013.

14.

Synovial fluid levels of bradykinin correlate with biochemical markers for cartilage degradation and inflammation in knee osteoarthritis.

Bellucci F, Meini S, Cucchi P, Catalani C, Nizzardo A, Riva A, Guidelli GM, Ferrata P, Fioravanti A, Maggi CA.

Osteoarthritis Cartilage. 2013 Nov;21(11):1774-80. doi: 10.1016/j.joca.2013.08.014. Epub 2013 Aug 11.

15.

Comparison between oral and intra-articular antinociceptive effect of dexketoprofen and tramadol combination in monosodium iodoacetate-induced osteoarthritis in rats.

Cialdai C, Giuliani S, Valenti C, Tramontana M, Maggi CA.

Eur J Pharmacol. 2013 Aug 15;714(1-3):346-51. doi: 10.1016/j.ejphar.2013.07.026. Epub 2013 Jul 23.

PMID:
23891968
16.

Characterization of a novel proinflammatory effect mediated by BK and the kinin B₂ receptor in human preadipocytes.

Catalioto RM, Valenti C, Liverani L, Giuliani S, Maggi CA.

Biochem Pharmacol. 2013 Aug 15;86(4):508-20. doi: 10.1016/j.bcp.2013.06.005. Epub 2013 Jun 21.

PMID:
23796753
17.

Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 1: hit identification.

Marastoni E, Bartoli S, Berettoni M, Cipollone A, Ettorre A, Fincham CI, Mauro S, Paris M, Porcelloni M, Bigioni M, Binaschi M, Nardelli F, Parlani M, Maggi CA, Fattori D.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4091-5. doi: 10.1016/j.bmcl.2013.05.053. Epub 2013 May 25.

PMID:
23768910
18.

New insight into the binding mode of peptides at urotensin-II receptor by Trp-constrained analogues of P5U and urantide.

Carotenuto A, Auriemma L, Merlino F, Limatola A, Campiglia P, Gomez-Monterrey I, di Villa Bianca Rd, Brancaccio D, Santicioli P, Meini S, Maggi CA, Novellino E, Grieco P.

J Pept Sci. 2013 May;19(5):293-300. doi: 10.1002/psc.2498. Epub 2013 Mar 25.

PMID:
23526702
19.

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J.

J Clin Oncol. 2013 Apr 20;31(12):1554-61. doi: 10.1200/JCO.2012.46.4057. Epub 2013 Mar 11.

20.

OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain.

Bressan A, Bozzo F, Maggi CA, Binaschi M.

Dis Markers. 2013;34(4):257-67. doi: 10.3233/DMA-130968.

21.

Characterization of ibodutant at NK(2) receptor in human colon.

Santicioli P, Meini S, Giuliani S, Catalani C, Bechi P, Riccadonna S, Ringressi MN, Maggi CA.

Eur J Pharmacol. 2013 Feb 28;702(1-3):32-7. doi: 10.1016/j.ejphar.2013.01.021. Epub 2013 Jan 29.

PMID:
23376417
22.

Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.

Bigioni M, Ettorre A, Felicetti P, Mauro S, Rossi C, Maggi CA, Marastoni E, Binaschi M, Parlani M, Fattori D.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5360-2. doi: 10.1016/j.bmcl.2012.07.067. Epub 2012 Jul 26.

PMID:
22877635
23.

SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.

Bellarosa D, Bressan A, Bigioni M, Parlani M, Maggi CA, Binaschi M.

Int J Oncol. 2012 Oct;41(4):1486-94. doi: 10.3892/ijo.2012.1551. Epub 2012 Jul 13.

PMID:
22797667
24.

Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin E₂ release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes.

Meini S, Cucchi P, Tinti L, Niccolini S, Bellucci F, Catalani C, Valenti C, Galeazzi M, Fioravanti A, Maggi CA.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Aug;385(8):777-86. doi: 10.1007/s00210-012-0762-y. Epub 2012 May 26.

PMID:
22638761
25.

Design and synthesis of novel sulfonamide-containing bradykinin hB(2) receptor antagonists. Synthesis and structure-relationships of α,α-tetrahydropyranylglycine.

Fincham CI, Bressan A, D'Andrea P, Ettorre A, Giuliani S, Mauro S, Meini S, Paris M, Quartara L, Rossi C, Squarcia A, Valenti C, Daniela F, Maggi CA.

Bioorg Med Chem. 2012 Mar 15;20(6):2091-100. doi: 10.1016/j.bmc.2012.01.036. Epub 2012 Jan 30.

PMID:
22342268
26.

Fasitibant chloride, a kinin B₂ receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats.

Valenti C, Giuliani S, Cialdai C, Tramontana M, Maggi CA.

Br J Pharmacol. 2012 Jun;166(4):1403-10. doi: 10.1111/j.1476-5381.2012.01861.x.

27.

4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.

Rossi C, Fincham CI, D'Andrea P, Porcelloni M, Ettorre A, Mauro S, Bigioni M, Binaschi M, Maggi CA, Nardelli F, Parlani M, Fattori D.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6767-9. doi: 10.1016/j.bmcl.2011.09.042. Epub 2011 Sep 18.

PMID:
21978679
28.

Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.

Rossi C, Porcelloni M, D'Andrea P, Fincham CI, Ettorre A, Mauro S, Squarcia A, Bigioni M, Parlani M, Nardelli F, Binaschi M, Maggi CA, Fattori D.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2305-8. doi: 10.1016/j.bmcl.2011.02.085. Epub 2011 Feb 26.

PMID:
21420859
29.

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

Binaschi M, Simonelli C, Goso C, Bigioni M, Maggi CA.

Exp Ther Med. 2011 Mar;2(2):173-180. Epub 2011 Jan 14.

30.

hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability.

Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1807-9. doi: 10.1016/j.bmcl.2011.01.074. Epub 2011 Feb 1.

PMID:
21320781
31.

Intestinal epithelial barrier dysfunction in disease and possible therapeutical interventions.

Catalioto RM, Maggi CA, Giuliani S.

Curr Med Chem. 2011;18(3):398-426. Review.

PMID:
21143118
32.

Comparison of the molecular interactions of two antagonists, MEN16132 or icatibant, at the human kinin B₂ receptor.

Meini S, Bellucci F, Catalani C, Cucchi P, Giolitti A, Giuliani S, Quartara L, Rotondaro L, Zappitelli S, Maggi CA.

Br J Pharmacol. 2011 Mar;162(5):1202-12. doi: 10.1111/j.1476-5381.2010.01133.x.

33.

Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.

Binaschi M, Boldetti A, Gianni M, Maggi CA, Gensini M, Bigioni M, Parlani M, Giolitti A, Fratelli M, Valli C, Terao M, Garattini E.

ACS Med Chem Lett. 2010 Jul 20;1(8):411-5. doi: 10.1021/ml1001163. eCollection 2010 Nov 11.

34.

Bradykinin and B₂ receptor antagonism in rat and human articular chondrocytes.

Meini S, Cucchi P, Catalani C, Bellucci F, Giuliani S, Maggi CA.

Br J Pharmacol. 2011 Feb;162(3):611-22. doi: 10.1111/j.1476-5381.2010.01062.x.

35.

Effect of otilonium bromide and ibodutant on the internalization of the NK2 receptor in human colon.

Cipriani G, Santicioli P, Evangelista S, Maggi CA, Riccadonna S, Ringressi MN, Bechi P, Faussone-Pellegrini MS, Vannucchi MG.

Neurogastroenterol Motil. 2011 Jan;23(1):96-102, e10. doi: 10.1111/j.1365-2982.2010.01594.x.

PMID:
20879991
36.

Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA.

Bressan A, Bigioni M, Bellarosa D, Nardelli F, Irrissuto C, Maggi CA, Binaschi M.

Oncol Rep. 2010 Nov;24(5):1249-55.

PMID:
20878117
37.

Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2.

Cialdai C, Giuliani S, Valenti C, Tramontana M, Maggi CA.

Naunyn Schmiedebergs Arch Pharmacol. 2010 Dec;382(5-6):455-61. doi: 10.1007/s00210-010-0563-0. Epub 2010 Sep 17.

PMID:
20848272
38.

Anti-inflammatory synergy of MEN16132, a kinin B(2) receptor antagonist, and dexamethasone in carrageenan-induced knee joint arthritis in rats.

Valenti C, Giuliani S, Cialdai C, Tramontana M, Maggi CA.

Br J Pharmacol. 2010 Dec;161(7):1616-27. doi: 10.1111/j.1476-5381.2010.00995.x.

39.

Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor.

Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.

J Med Chem. 2010 May 27;53(10):4148-65. doi: 10.1021/jm100176s.

PMID:
20408549
40.

Radioligand binding characterization of the bradykinin B(2) receptor in the rabbit and pig ileal smooth muscle.

Meini S, Cucchi P, Catalani C, Bellucci F, Santicioli P, Giuliani S, Maggi CA.

Eur J Pharmacol. 2010 Jun 10;635(1-3):34-9. doi: 10.1016/j.ejphar.2010.03.012. Epub 2010 Mar 20.

PMID:
20307535
41.

Tachykinin receptor assays.

Meini S, Maggi CA.

Curr Protoc Pharmacol. 2010 Mar;Chapter 4:Unit 4.10. doi: 10.1002/0471141755.ph0410s48.

PMID:
22294370
42.

Influence of tachykinin NK2 receptors on intestinal sensitivity and motility in newborn rats.

Tramontana M, Evangelista S, Giuliani S, Manzini S, Robelet S, Girod V, Maggi CA.

Neuropeptides. 2010 Jun;44(3):269-72. doi: 10.1016/j.npep.2010.01.002.

PMID:
20137809
43.

Novel effects mediated by bradykinin and pharmacological characterization of bradykinin B2 receptor antagonism in human synovial fibroblasts.

Bellucci F, Cucchi P, Catalani C, Giuliani S, Meini S, Maggi CA.

Br J Pharmacol. 2009 Dec;158(8):1996-2004.

44.

Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK(2) receptor antagonists.

Gensini M, Altamura M, Dimoulas T, Fedi V, Giannotti D, Giuliani S, Guidi A, Harmat NJ, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.

ChemMedChem. 2010 Jan;5(1):65-78. doi: 10.1002/cmdc.200900389.

PMID:
19957262
45.

Tachykinin receptor antagonists in clinical trials.

Quartara L, Altamura M, Evangelista S, Maggi CA.

Expert Opin Investig Drugs. 2009 Dec;18(12):1843-64. doi: 10.1517/13543780903379530. Review.

PMID:
19938899
46.

Chemically distinct HDAC inhibitors prevent adipose conversion of subcutaneous human white preadipocytes at an early stage of the differentiation program.

Catalioto RM, Maggi CA, Giuliani S.

Exp Cell Res. 2009 Nov 15;315(19):3267-80. doi: 10.1016/j.yexcr.2009.09.012. Epub 2009 Sep 18.

PMID:
19766628
48.

Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.

Bigioni M, Parlani M, Bressan A, Bellarosa D, Rivoltini L, Animati F, Crea A, Bugianesi R, Maggi CA, Manzini S, Binaschi M.

Int J Cancer. 2009 Nov 15;125(10):2456-64. doi: 10.1002/ijc.24661.

49.

Pharmacological characterization of the bradykinin B2 receptor antagonist MEN16132 in rat in vitro bioassays.

Meini S, Cucchi P, Catalani C, Bellucci F, Giuliani S, Santicioli P, Maggi CA.

Eur J Pharmacol. 2009 Aug 1;615(1-3):10-6. doi: 10.1016/j.ejphar.2009.04.057. Epub 2009 May 13.

PMID:
19445925
50.

New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.

Grieco P, Carotenuto A, Campiglia P, Gomez-Monterrey I, Auriemma L, Sala M, Marcozzi C, d'Emmanuele di Villa Bianca R, Brancaccio D, Rovero P, Santicioli P, Meini S, Maggi CA, Novellino E.

J Med Chem. 2009 Jul 9;52(13):3927-40. doi: 10.1021/jm900148c.

PMID:
19432421

Supplemental Content

Loading ...
Support Center